3-[(Imidazolidin-2-yl)imino]indazole ligands with selectivity for the α2-adrenoceptor compared to the imidazoline I1 receptor

Bioorganic and Medicinal Chemistry

Volumn 19, Issue 1, 2011, Pages 321-329

  Sczewski, Franciszek ^a   Kornicka, Anita ^a   Hudson, Alan L ^b   Laird, Shayna ^b   Scheinin, Mika ^c   Laurila, Jonne M ^c   Rybczyńska, Apolonia ^a   Boblewski, Konrad ^a   Lehmann, Artur ^a   Gdaniec, Maria ^d  

^a MEDICAL UNIVERSITY OF GDANSK   (Poland)

^b UNIVERSITY OF ALBERTA   (Canada)

^c TURKU UNIVERSITY HOSPITAL   (Finland)

^d ADAM MICKIEWICZ UNIVERSITY   (Poland)

Author keywords

Alpha2 adrenenoceptor agonists; Hypotensive agents; Imidazolines; Indazoles; Synthesis; X ray structure

Indexed keywords

3 [(IMIDAZOLIDIN 2 YL)IMINO] 4 METHOXYINDAZOLE; 3 [(IMIDAZOLIDIN 2 YL)IMINO] 4 METHYLINDAZOLE; 3 [(IMIDAZOLIDIN 2 YL)IMINO] 5 METHOXYLINDAZOLE; 3 [(IMIDAZOLIDIN 2 YL)IMINO] 5 METHYLINDAZOLE; 3 [(IMIDAZOLIDIN 2 YL)IMINO] 6 METHYLINDAZOLE; 3 [(IMIDAZOLIDIN 2 YL)IMINO]INDAZOLE; 4 BROMO 3[(IMIDAZOLIDIN 2 YL)IMINO]INDAZOLE; 4 CHLORO 3[(IMIDAZOLIDIN 2 YL)IMINO]INDAZOLE; 4 CHLORO MARSANIDINE; 5 CHLORO 3[(IMIDAZOLIDIN 2 YL)IMINO]INDAZOLE; 6 CHLORO 3[(IMIDAZOLIDIN 2 YL)IMINO]INDAZOLE; 7 CHLORO 3[(IMIDAZOLIDIN 2 YL)IMINO]INDAZOLE; 7 CHLORO MARSANIDINE; 7 METHYL MARSANIDINE; ALPHA 2 ADRENERGIC RECEPTOR; ALPHA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; CLONIDINE; DEXMEDETOMIDINE; IMIDAZOLINE I1 RECEPTOR; INDAZOLE DERIVATIVE; MARSANIDINE; NORADRENALIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CARDIOVASCULAR EFFECT; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DRUG ACTIVITY; DRUG SELECTIVITY; DRUG SYNTHESIS; MALE; MEAN ARTERIAL PRESSURE; NONHUMAN; RAT; RECEPTOR AFFINITY;

ANIMALS; IMIDAZOLINE RECEPTORS; INDAZOLES; LIGANDS; RADIOLIGAND ASSAY; RATS; RECEPTORS, ADRENERGIC, ALPHA-2;

RATTUS;

EID: 78650747258     PISSN: 09680896     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmc.2010.11.020     Document Type: Article

References (30)

1. W. Kobinger Naunyn-Schmiedeberg's Arch. Pharmacol. 332 1986 113
2. B.T. Armach Arzneim.-Forsch. Drug Res. 38 1988 1435
3. P.A. Van Zweiten Am. J. Cardiol. 61 1988 D6
4. W. Kobinger, and L. Pichler Centrally Acting Drugs (Clonidine, Methyldopa, Guanfacine) D. Ganten, P.J. Murlow, Handbook of Experimental Pharmacology. Pharmacology of Antihypertensive Therapeutics Vol. 93 1990 Springer Berlin 227
5. R.R. Ruffolo Jr., A.J. Nichols, J.M. Stadel, and J.P. Hieble Annu. Rev. Pharmacol. Toxicol. 32 1993 243
6. R.D. Sanders, and M. Maze Curr. Opin. Invest. Drugs 8 2007 25
7. J. Mantz Bailliere's Clin. Anaesthesiol. 14 2000 433
8. Z.P. Khan, C.N. Ferguson, and R.M. Jones Anaesthesia 54 1999 146
9. M. Philipp, M. Brede, and L. Hein Am. J. Physiol. Regul. Integr. Comp. Physiol. 283 2002 R287
10. G.A. Head, S.L. Burke, and C.K. Chan Clin. Exp. Hypertens. 19 1997 591
11. P. Bousquet Am. J. Hypertens. 14 2001 317S
12. L.B. MacMillan, L. Hein, M.S. Smith, M.T. Piascik, and L.E. Limbird Science 273 1996 801
13. Q.-M. Zhu, J.D. Lesnick, J.R. Jasper, S.J. MacLennan, M.P. Dillon, R.M. Eglen, and D.R. Blue Jr. Br. J. Pharmacol. 126 1999 1522
14. B. Szabo Pharmacol. Ther. 93 2002 1
15. F. Sczewski, A. Kornicka, A. Rybczyńska, A.L. Hudson, S.S. Miao, M. Gdaniec, K. Boblewski, and A. Lehmann J. Med. Chem. 51 2008 3599
16. K. Lukin, M.C. Hsu, F. Dilinie, and M.R. Leanna J. Org. Chem. 71 2006 8166
17. G. Voss, and S. Eichner J. Prakt. Chem. 342 2000 201
18. A. Vasudevan, A.J. Souers, J.C. Freeman, M.K. Verzal, J. Gao, M.M. Mulhern, D. Wodka, J.K. Lynch, K.M. Engstrom, S.H. Wagaw, S. Brodjian, B. Dayton, D.H. Falls, E. Bush, M. Brune, R.D. Shapiro, K.C. Marsh, L.E. Hernandez, Ch.A. Collins, and P.R. Kym Bioorg. Med. Chem. Lett. 15 2005 5293
19. S.R. Mundla, L.J. Wilson, S.R. Klopfenstein, W.L. Seibel, and N.N. Nikolaides Tetrahedron Lett. 41 2000 6563
20. The geometry of marsanidine A and its analogue 3a were fully optimized by DFT method at the B3LYP/6-31G level using Spartan program. Total energies, atomic charges and 3D electrostatic potential maps were calculated at the same level.
21. a values were determined at 25 °C by potentiometric titration using Metrohm 794 Titrino apparatus with the TiNet 2.5 software.
22. Y.C. Cheng, and W.H. Prusoff Biochem. Pharmacol. 22 1973 3099
23. J.M. Peltonen, M. Pihlavisto, and M. Scheinin Eur. J. Pharmacol. 355 1998 275
24. M.M. Bradford Anal. Biochem. 7 1976 248
25. T. Olli-Lahdesmaki, M. Tiger, M. Vainio, M. Scheinin, and J. Kallio Biochem. Biophys. Res. Commun. 321 2004 226
26. A. Rybczyńska, K. Boblewski, A. Lehmann, C. Orlewska, H. Foks, K. Drewnowska, and A. Hoppe Am. J. Hypertens. 18 2005 364
27. L.A. Lione, D.J. Nutt, and A.L. Hudson Eur. J. Pharmacol. 353 1998 123
28. P. Ernsberger, M.E. Graves, L.M. Graff, N. Zakieh, P. Nguyen, L.A. Collins, K.L. Westbrooks, and G.G. Johnson Ann. N.Y. Acad. Sci. 763 1995 22
29. A.L. Hudson, C.B. Chapleo, J.W. Lewis, S. Husbands, K. Grivas, N.J. Mallard, and D. Nutt J. Neurochem. Int. 30 1997 47
30. D.J. Nutt, N. French, S. Haudley, A.L. Hudson, S. Husbands, H. Jackson, S. Jordan, M. Lalies, J. Lewis, L. Lione, N. Mallard, and J. Pratt Ann. N.Y. Acad. Sci. 763 1995 125